Latest in Novo Nordisk shares tumble as weight loss drug trial data disappoints
Sort by
683 items
-
Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point Friday after reporting trial results that missed expectations.CNBC - 54m -
Novo Nordisk’s drug stumble leaves it suddenly much slimmer
Market will never be winner takes all given that different patients will have different requirementsFinancial Times - 4h -
Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints
Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.MarketWatch - 5h -
Novo Nordisk shares tumble as weight-loss drug trial data disappoints
Obesity drug CagriSema misses goal of 25% body weight reductionFinancial Times - 8h -
Micron shares suffer steepest drop since 2020 after disappointing guidance
Micron's stock plummeted Thursday following the company's earnings report and its weaker-than-expected guidance for the second quarter.CNBC - 23h -
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
The decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.CNBC - 1d -
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.
In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.The New York Times - 1d -
FDA warns companies over unapproved weight loss drug sales
The Food and Drug Administration (FDA) said Tuesday in a statement it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides, Swisschems, ...The Hill - 2d -
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.CNBC - 2d -
Tennessee woman accused of selling fake weight loss drugs as counterfeit concerns grow
A Tennessee woman was accused of selling counterfeit versions of popular weight loss drugs including Ozempic. Experts say fakes have exploded in the U.S.NBC News - 2d -
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition
A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.CNBC - 2d -
Bayer Eye Drug Shows Positive Results in Late-Stage Trial
Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.The Wall Street Journal - 3d -
Canal+ shares slump a fifth on disappointing London debut
UK chancellor Rachel Reeves had hailed listing as vote of confidence in marketFinancial Times - 4d -
Why the investor craze for Ozempic and rival weight-loss drugs may resume next year
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts saidMarketWatch - 4d -
Novo Nordisk to invest $1.2 billion in new plant in Denmark
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday. "Designed to be ...Yahoo Sports - 4d -
In shift, RFK Jr. now says weight-loss drugs 'have a place'
His remarks come days before he holds confirmation meetings with GOP senators.ABC News - Dec. 12 -
Elon Musk contradicts RFK Jr.'s sentiments on weight loss drugs
Elon Musk validated the use of GLP-1 drugs in a post on X on Wednesday. But Robert F. Kennedy Jr. has said he's opposed to Americans using them to fight obesity.ABC News - Dec. 12 -
Adobe shares suffer steepest drop in over two years on disappointing revenue guidance
Adobe shares tumbled after the software vendor issued revenue guidance that fell short of analysts' estimates.CNBC - Dec. 12 -
What other conditions could weight-loss drugs treat?
Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’sFinancial Times - Dec. 12 -
Adobe disappoints investors in this crucial metric, and shares fall nearly 9%
A weaker outlook clouded an otherwise OK quarter for the software company amid rising competition in AI.MarketWatch - Dec. 11 -
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.CNBC - Dec. 11 -
We're buying more shares of a company that makes a key part of AI data centers
Last month, we raised our price target after the CEO appeared on "Mad Money."CNBC - Dec. 10 -
Oracle shares slide on earnings and revenue miss, disappointing forecast
Oracle shares fell Tuesday morning after the database software company issued disappointing quarterly results.CNBC - Dec. 10 -
Some health experts warn against microdosing weight loss drugs
The demand for weight loss drugs, like Ozempic and Wegovy, has skyrocketed in the past few years despite the high cost and unpleasant side effects for some people. The New York Times reports some ...CBS News - Dec. 9 -
Comcast shares tumble as executive calls broadband 'intensely competitive'
Comcast shares fell Monday after its cable CEO called broadband "competitively intense," and expects to lose more than 100,000 customers in the fourth quarter.CNBC - Dec. 9 -
College basketball rankings: Kansas' upset loss at Missouri sends Jayhawks tumbling in Top 25 And 1
KU's loss to the Tigers was the second time this week it dropped a nonconference game on the roadCBS Sports - Dec. 9 -
Giants' latest 'disappointing' loss keeps hope of landing No. 1 pick alive
Graham Gano’s miss sealed the Giants’ 14-11 loss to the lowly Saints. More importantly: It kept the possibility of the No. 1 pick in the NFL Draft alive.Yahoo Sports - Dec. 9 -
The weight-loss drug boom has become one of the internet's biggest scams
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.CNBC - Dec. 8 -
Weight-loss drug Mounjaro 'changed my life,' says mother-of-two
People struggling with their weight welcome the NHS rollout of Mounjaro but worry about delays.BBC News - Dec. 5 -
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.CNBC - Dec. 5 -
Millions will have to wait up to 12 years for NHS weight-loss drug
Fears that giving 3.4 million people immediate access to new weight-loss drug could overwhelm NHS.BBC News - Dec. 5 -
Foot Locker shares tumble as it issues gloomy holiday outlook, sees 'softness' at Nike
Foot Locker fell short of Wall Street expectations and cut its guidance after sales declined more than expected.CNBC - Dec. 4 -
Will Trump nix Biden’s coverage plan for weight-loss drugs? It’ll be a close call.
While President-elect Donald Trump looks poised to scrap many policies of the Biden administration, one veteran analyst says it’s possible he could end up supporting the Democratic incumbent’s ...MarketWatch - Dec. 4 -
Zepbound brings more weight loss than Wegovy: Drugmaker
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from their ...The Hill - Dec. 4 -
Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next
New trial data has cemented Club holding Eli Lilly's pole position in the highly competitive weight loss drug race.CNBC - Dec. 4 -
Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy
Zepbound helped patients lose more weight than a major rival in a head-to-head trial.MarketWatch - Dec. 4 -
A rival weight loss drug to Wegovy helped people shed more pounds, study shows
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.NBC News - Dec. 4 -
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.CNBC - Dec. 4 -
Experts create controllable gastric balloon to aid weight loss
Device inflates before eating and contracts afterwards, simulating the effects of having a meal, say scientists. From weight loss jabs to vibrating pills , the obesity crisis has spawned myriad ...The Guardian - Dec. 3 -
Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial
Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.MarketWatch - Dec. 3
